Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Development of a glycan microarray based method for ABO blood typing

ABSTRACT: Purpose: This study uses a high-throughput glycan microarray to develop a novel method to assign ABO blood type. The method will then be applied to samples from patients treated with PROSTVAC to determine if blood type correlates with survival Results: Many blood group A and B antigens correlate with blood type. Blood typing is best achieved using a combination of 10 signals Conclusion: ABO blood type can be determined with greater than 97% accuracy using only 4 microliters of serum.

ORGANISM(S): Bos taurus Dermestes lardarius Mus musculus Homo sapiens Ovis aries Gossypium hirsutum Frangula alnus Trypanosoma cruzi Pachymenia carnosa Quercus alba Ceratonia siliqua Rhodotorula Pandalus borealis Megathura crenulata Senegalia senegal Gallus gallus Bothrops moojeni Oncorhynchus nerka

PROVIDER: GSE68403 | GEO | 2016/04/28

SECONDARY ACCESSION(S): PRJNA282665

REPOSITORIES: GEO

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
		Other

Items per page:

1 - 1 of 1

Similar Datasets

Determination of ABO blood type for prostate cancer patients

Project description:Purpose: This study uses a high-throughput glycan microarray to assign ABO blood type to patients from a clinical trial on PROSTVAC. The goal is to determine if blood type correlates with survival for patients treated with PROSTVAC Results: Blood types were assigned and type B and O patients were found to have longer survival than type A and AB patients Conclusion: Blood type may serve as a convenient method to identify patients likely to respond favorably to PROSTVAC therapy

2016-04-28 | GSE68404 | GEO

Homo sapiens

Project description:Development of a glycan microarray based method for ABO blood typing

| PRJNA282665 | ENA

Development of a Trypanosoma cruzi Strain Typing Assay using MS2 peptide spectral libraries (Tc-STAMS2)

Project description:Chagas disease is one of the most important neglected diseases with an estimated number of 12 million infected individuals, the majority living in Central and South America. The Trypanosoma cruzi (T.cruzi) protozoan parasite is the etiological agent of Chagas disease. T.cruzi is highly genetically diverse and a new nomenclature assigned each strain to seven genetic groups (TcI-TcVI and Tcbat), named Discrete Typing Units (DTUs), based on their biochemical, immunological and phenotypical characteristics. T.cruzi DTUs have been correlated to diverse clinical outcomes highlighting the importance of molecular epidemiological screens. Despite the development of T.cruzi typing methods based on genetic signatures, each method presenting its own advantages and challenges. The work presented here shows the application of mass spectrometry for Trypanosoma cruzi Strain Typing Assay using MS2 peptide spectral libraries (Tc-STAMS2). The novelty of the method is based on the use of peptide fragmentation spectra as strain-specific fingerprints to classify and identify DTUs. Initially, a spectra library is generated from characterized T.cruzi strains. The library is subsequently inspected using MS/MS spectra from unknown strains and confidently assigned to a specific strain in an automated and computationally-driven approach. The Tc-STAMS2 method was challenged to test several variables such as sample type and preparation, instrument setup and identification platform. Tc-STAMS2 provided high confidence and robustness in T.cruzi strain typing. The Tc-STAMS2 method represents a proof-of-concept of a complementary strategy to the current DNA-based T. cruzi genotyping methods. Moreover, the method allows the identification of strain-specific features that could be related to the biology of T.cruzi strains and their clinical outcomes.

2018-03-19 | PXD008088 | Pride

Clostridium difficile typing

Project description:Clostridium difficile typing

| PRJEB656 | ENA

Class I Typing

Project description:Class I Typing

| PRJEB33618 | ENA

Listeria monocytogenes Typing

Project description:Typing of Listeria monocytogenes.

| PRJEB5481 | ENA

Oxford Nanopore RNA sequencing for HLA typing

Project description:A targeted RNA-based method for typing of 12 classical HLA genes using Oxford Nanopore sequencing. In the method, were enriched HLA genes from cDNA of 50 individuals using gene-specific reverse primers. The library molecules were then barcoded, pooled into 2 separate gene pools, and sequenced on MinION R9.4 SpotON flow cells.

| EGAS00001004918 | EGA

Homo sapiens

Project description:Determination of ABO blood type for prostate cancer patients

| PRJNA282664 | ENA

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgM 1:50]

Project description:Purpose: There is evidence that therapeutic cancer vaccines can lengthen survival for some cancer patients, but responses vary widely from one person to another. Methods to predict clinical outcomes will advance the field and provide new insights into critical determinants of in vivo efficacy. This study uses a high-throughput glycan microarray to assess correlations between a subject's overall survival after receiving PROSTVAC-VF and his baseline serum anti-glycan antibody levels. Results: Pre-vaccination antibody levels to blood group A trisaccharide (BG-Atri) were found to have a statistically significant correlation with survival. Long-term survival was approximately doubled in subjects with abundant anti-BG-Atri IgM relative to subjects with little or no pre-existing IgM for BG-Atri. This survival correlation was specific to vaccine treatment, as no correlation was observed in control patients immunized with wild-type poxviruses lacking the key tumor antigen, prostate specific antigen (PSA). Moreover, anti-BG-Atri IgM levels were not correlated with general measures of disease severity, such as PSA levels, Gleason score, or Halabi predicted survival. Conclusion: In addition to reporting a new potentially predictive biomarker for PROSTVAC-VF, this study highlights the potential of glycan microarray technology for personalized medicine.

2013-04-01 | GSE42020 | GEO

Baseline serum anti-glycan antibodies of 28 subjects in a clinical trial of PROSTVAC-VF, a therapeutic cancer vaccine [Training IgG 1:50]

2013-04-01 | GSE42019 | GEO